Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
24
02
2023
accepted:
16
08
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Currently, the influence of the tumor microbiome on the effectiveness of immunotherapy remains largely unknown. Intratumoural Fusobacterium nucleatum (Fn) functions as an oncogenic bacterium and can promote tumor progression in esophageal squamous cell carcinoma (ESCC). Our previous study revealed that Fn is a facultative intracellular bacterium and that its virulence factor Fn-Dps facilitates the intracellular survival of Fn. In this study, we find that Fn DNA is enriched in the nonresponder (NR) group among ESCC patients receiving PD-1 inhibitor and that the serum antibody level of Fn is significantly higher in the NR group than in the responder (R) group. In addition, Fn infection has an opposite impact on the efficacy of αPD-L1 treatment in animals. Mechanistically, we confirm that Fn can inhibit the proliferation and cytokine secretion of T cells and that Fn-Dps binds to the PD-L1 gene promoter activating transcription factor-3 (ATF3) to transcriptionally upregulate PD-L1 expression. Our results suggest that it may be an important therapeutic strategy to eradicate intratumoral Fn infection before initiating ESCC immunotherapies.
Identifiants
pubmed: 37723150
doi: 10.1038/s41467-023-40987-3
pii: 10.1038/s41467-023-40987-3
pmc: PMC10507087
doi:
Substances chimiques
B7-H1 Antigen
0
Activating Transcription Factor 3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5788Informations de copyright
© 2023. Springer Nature Limited.
Références
Oncotarget. 2017 May 2;8(18):30175-30189
pubmed: 28404915
Front Microbiol. 2019 Aug 02;10:1780
pubmed: 31428073
PLoS Pathog. 2019 Jan 31;15(1):e1007468
pubmed: 30703170
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Genes Dis. 2021 Jun 03;9(4):981-999
pubmed: 35685455
Nat Biomed Eng. 2022 Jan;6(1):44-53
pubmed: 35058589
Infect Immun. 2018 Apr 23;86(5):
pubmed: 29440366
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Gut. 2020 Nov 10;:
pubmed: 33172926
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
Aging (Albany NY). 2022 Feb 25;14(4):1941-1958
pubmed: 35212644
Cancer Immunol Res. 2020 Oct;8(10):1243-1250
pubmed: 32847937
Free Radic Res. 2006 Jun;40(6):597-605
pubmed: 16753837
Br J Cancer. 2023 Apr;128(6):1155-1165
pubmed: 36599917
Cancer Sci. 2020 Sep;111(9):3132-3141
pubmed: 32579769
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
Clin Cancer Res. 2019 Oct 15;25(20):6170-6179
pubmed: 31358543
Nature. 2006 May 11;441(7090):173-8
pubmed: 16688168
Nat Rev Microbiol. 2019 Mar;17(3):156-166
pubmed: 30546113
J Cell Physiol. 2019 Mar;234(3):2337-2344
pubmed: 30191984
Cancer Cell. 2020 Mar 16;37(3):324-339.e8
pubmed: 32183950
Nat Commun. 2020 Jun 26;11(1):3259
pubmed: 32591509
Clin Cancer Res. 2016 Nov 15;22(22):5574-5581
pubmed: 27769987
Eur J Clin Invest. 2023 Feb;53(2):e13880
pubmed: 36164962
Signal Transduct Target Ther. 2021 Nov 19;6(1):398
pubmed: 34795206
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Gut. 2022 Mar;71(3):457-466
pubmed: 34253574
Front Cell Infect Microbiol. 2022 Jun 29;12:935806
pubmed: 35846769
JAMA Oncol. 2015 Aug;1(5):653-61
pubmed: 26181352
Cell Host Microbe. 2023 May 10;31(5):781-797.e9
pubmed: 37130518
Cell Death Dis. 2018 Mar 2;9(3):355
pubmed: 29500439
Gastroenterology. 2021 Jan;160(2):600-613
pubmed: 33253684
Biometals. 2012 Apr;25(2):423-33
pubmed: 22203404
Br J Cancer. 2021 Mar;124(5):963-974
pubmed: 33299132
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
BMC Cancer. 2022 Aug 19;22(1):904
pubmed: 35986342
Onco Targets Ther. 2022 Feb 28;15:201-213
pubmed: 35250279
Cell Host Microbe. 2013 Aug 14;14(2):207-15
pubmed: 23954159
World J Gastroenterol. 2016 Jan 14;22(2):557-66
pubmed: 26811607
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Immunol Lett. 2015 Oct;167(2):131-40
pubmed: 26292028
Infect Immun. 2010 Nov;78(11):4773-8
pubmed: 20823215
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Cancer Lett. 2022 Apr 1;530:59-67
pubmed: 35033591
Immunity. 2015 Feb 17;42(2):344-355
pubmed: 25680274
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Gut Microbes. 2020 May 3;11(3):511-525
pubmed: 31910722
Infect Immun. 1996 Apr;64(4):1335-41
pubmed: 8606098
Cancer Med. 2019 Aug;8(10):4519-4526
pubmed: 31231980
PLoS Pathog. 2023 Jan 24;19(1):e1011096
pubmed: 36693067